TY - JOUR
T1 - Type i interferons
T2 - Ancient peptides with still under-discovered anti-cancer properties
AU - Caraglia, Michele
AU - Dicitore, Alessandra
AU - Marra, Monica
AU - Castiglioni, Sara
AU - Persani, Luca
AU - Sperlongano, Pasquale
AU - Tagliaferri, Pierosandro
AU - Abbruzzese, Alberto
AU - Vitale, Giovanni
PY - 2013/4
Y1 - 2013/4
N2 - Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
AB - Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-α, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-α, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN-α is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
KW - Egf-p
KW - Farnesyltransferase inhibitors
KW - Interferon-alpha
KW - Interferon-beta
KW - Mtor
KW - Pegylated interferons
KW - Stats
KW - Type i interferons
UR - http://www.scopus.com/inward/record.url?scp=84877959168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877959168&partnerID=8YFLogxK
U2 - 10.2174/092986613805290372
DO - 10.2174/092986613805290372
M3 - Article
C2 - 23016588
AN - SCOPUS:84877959168
VL - 20
SP - 412
EP - 423
JO - Protein and Peptide Letters
JF - Protein and Peptide Letters
SN - 0929-8665
IS - 4
ER -